Clinical Outcome of the HBsAg Positive Malignant Lymphoma Patients Following Anticancer Chemotherapy.
- Author:
Bon Kwon KU
1
;
Jee Sook HAHN
;
Kwang Hyub HAHN
;
Seung Tae LEE
;
Hyung Chan SUH
;
Kun Ho KWON
;
Jin Hun LEE
;
Yoo Hong MIN
;
Yun Woong KO
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Malignant lymphoma;
Hepatitis B;
Anticancer chemotherapy
- MeSH:
Academic Medical Centers;
Drug Therapy*;
Follow-Up Studies;
Hematologic Neoplasms;
Hepacivirus;
Hepatitis;
Hepatitis B;
Hepatitis B e Antigens;
Hepatitis B Surface Antigens*;
Hepatitis B virus;
Humans;
Incidence;
Interferon-alpha;
Interferons;
Lymphoma*;
Serologic Tests
- From:Korean Journal of Medicine
1997;52(4):542-549
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Infection and replication of the hepatitis B virus are closely related to the host immunity. Anticancer chemotherapy decreases the immune response of the host, Especially, glucocorticoid can activate the replication of hepatitis B virus directly. It is well known that hepatitis B virus infection and hepatic complications are more common in patients with hematologic malignancies like malignant lymphoma. We studied the incidence of hepatitis B virus infection and hepatic complications following anti-cancer chemotherapy in patients with malignant lymphoma. METHODS: Among 224 cases diagnosed as malignant lymphoma from January 1989 to December 1993 at Yonsei University Medical Center, 77 cases tested for hepatitis B virus serology was studied. RESULTS: 1) Eighteen cases (23%) was HBsAg positive. 2) The results of hepatitis C virus serology in six cases were all negative. 3) Eight (57%) of 14 follow-up cases had hepatic complications, Two patients had fulminant hepatitis, two nonicteric hepatitis and four icteric hepatitis. 4) Interferon-alpha was administered in three cases among the patients with hepatic complications. Loss of HBeAg was observed in one case and loss of HBsAg in another case. CONCLUSION: Serious hepatic complications can be occurred following anticancer chemotherapy in HBsAg-positive patients with malignant lymphoma. Therefore, we recommend that patients being considered as candidates for anticancer chemotherapy should routinely undergo serologic test for Hepatitis B virus. In addition HBsAg-positive patients with anticancer chemotherapy should be regularly monitored for hepatic injury. And with the careful use of steroid and interferon, prolongation of survival might be searched for these patients.
